Floatz logo

Neoantigen Specific Tcr-T Cell Drug Product

Lung Adenocarcinoma

Alaunos TherapeuticsCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

67 Active assets in the Lung Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Guangdong Association of Clinical Trials
Phase 3BBB
Cyclophosphamide
Anusha Kalbasi
Phase 2BBB
Nivolumab
Emory University
Phase 3BB
ETOPOSIDE
Guangdong Association of Clinical Trials
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Guangdong Association of Clinical Trials
Phase 3BB

View all 50 →

Same molecule, other indications

Neoantigen Specific Tcr-T Cell Drug Product is also rated in:

ovarian neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
adenosquamous lung carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →
squamous cell lung carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →